The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation
Scientific Reports - United Kingdom
doi 10.1038/srep27886
Full Text
Open PDFAbstract
Available in full text
Categories
Date
June 13, 2016
Authors
Publisher
Springer Science and Business Media LLC